https://www.selleckchem.com/products/cnqx.html
We explored the outcome of convalescent plasma (CP) treatment in patients with moderate and severe coronavirus disease 2019 (COVID-19) and investigated variables for the design of further trials in Indonesia. Hospitalised patients with moderate ( =5) and severe ( =5) COVID-19 were recruited and transfused with CP from donors who recovered from mild ( =5), moderate ( =5), or severe ( =1) COVID-19. Neutralising antibodies (NAbs) to the virus were measured at the end of the study using a surrogate virus neutralisation test as an alternative t
Like
Comment
Share
